|
|
Browse Publications
 Published: 2010 This report details key IAVI activities in 2009 related to research and development, policy and advocacy, and country-level and global programs on our mission to develop a safe, effective accessible, preventive HIV vaccine for all. |  Published: 2010 IAVI is a global not-for-profit, public-private partnership working to accelerate the development of a vaccine to prevent HIV infection and AIDS. This information sheet details the organization's mission and activities. |  Published: 2010 This brief investigates the potential impact of partially effective AIDS vaccines on the concentrated AIDS epidemic in Brazil. It also explores various vaccination strategies. This brief was produced in collaboration with the Brazilian Ministry of Health, IPEC-FIOCRUZ and the Futures Institute. |  Published: 2010 This policy brief, produced through a collaboration between IAVI, the Brazilian Association of Collective Health, and the Brazilian National AIDS Department, explores how targeted policy reforms focusing on collaboration, product development capacity, and financing and regulatory coordination could accelerate Brazil’s participation in AIDS vaccine R&D. |  Published: June 2010 This new IAVI Policy Note summarizes key findings from Policy Brief #20 “Estimating the Potential Impact of an AIDS Vaccine in Developing Countries”. It examines the future trajectory of the AIDS pandemic in developing countries, the potential impact that an AIDS vaccine could have on the pandemic, and the cost-saving potential of a future AIDS vaccine. |  Published: 2010 Vaccine preparedness is a comprehensive, partnership-based approach to help countries and communities involved in AIDS vaccine research and to generate support for such efforts in the global community. This brief describes IAVI’s approach to vaccine preparedness and the core strategies used to meet the challenges of conducting this work in low-income countries hit hardest by HIV. | Published: January-February 2010 In this issue:
- On the Scientific Trail in Santa Fe: A walk through some of the pioneering research presented at the annual Keystone Symposia on HIV Biology and Pathogenesis
- Antibodies: Beyond Neutralization: In the search for correlates of protection, AIDS vaccine researchers are once again starting to look beyond the classic neutralizing antibody responses
- Prevent and Conquer: A collection of key research updates that headlined this year’s Conference on Retroviruses and Opportunistic Infections
- Research Briefs: Adding to the Armamentarium of Broadly Neutralizing Antibodies
- Vaccine Briefs: Ushering in the Decade of Vaccines; Journal Retracts Controversial Article that Spurred Anti-vaccine Sentiment; 2011 US Budget Proposal Calls for Increase in HIV/AIDS Spending
| Published: March-April 2010 In this issue:
- Antibody Fever: Characterization of the slew of recently discovered broadly neutralizing antibodies was one of the advances highlighted at the recent HIV Vaccines conference
- Investing in Surprise: Efficacy trials may be costly, but some researchers argue that they are the best way to advance AIDS vaccine research and development
- Research Briefs: New Insights on Antibody Inhibition of Cell-associated HIV Spread; CMV Superinfection No Longer Shrouded in Mystery
- Vaccine Briefs: Investigators Tap Social Networking to Pique Interest in Vaccine Trial; CDC Creates New Center for Global Health
| Published: May-June 2010 In this issue:
- Tracking HIV Evolution: Theoretical biologist Bette Korber’s career has been devoted to classifying one of the most variable viruses ever identified.
- Meeting of the Minds on Mucosal Transmission: Researchers underscore the possible role of non-neutralizing antibodies in protection against HIV and discuss ways to optimize animal models to study mucosal transmission.
- An Interview with Michel Sidibé: The executive director of UNAIDS talks about AIDS funding, his hope for a vaccine and a cure, and a sustainable approach to HIV treatment.
- Research Briefs: Crystal Structure of PG16 Antigen-Binding Portion Reveals Unusual Features; Possible Explanation for HLA-class I Associated Control of HIV Infection.
- Vaccine Briefs: Researchers Unveil Plans for Follow-up Trials to RV144; US Government Singles Out Eight Countries for Pilot Program on Global Health Initiative.
| Published: July-August 2010 In this issue:
- Vaccines to Antibodies: Grow Up!: All of the HIV-specific antibodies identified so far have accumulated multiple mutations—some of which are required for them to bind to and neutralize HIV—through a process called affinity maturation. Researchers are now beginning to grapple with what this means for vaccine design.
- Microbicides Finally Gel, Securing Spotlight at the International AIDS Conference: The efficacy of a microbicide candidate was the definitive bright spot at this year’s conference, while the lingering economic slowdown and its impact on HIV/AIDS funding were dark clouds on the horizon.
- A Systems Approach to Understanding Vaccines: Researchers are starting to apply the tools of systems biology to better understand human immune responses to vaccination, including HIV vaccine candidates.
- Research Briefs: 3-D Structure of Dendritic Cell-T Cell Virological Synapses Revealed.
- Vaccine Briefs: First US National AIDS Strategy Aims to Cut New Infections and Optimize Care; Vaccine Candidate Targeting Dendritic Cells Enters Clinical Trial.
|
|
|
|
|